文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌根治性放疗联合可吸收间隔水凝胶后的患者报告生活质量结局

Patient Reported Quality of Life Outcomes After Definitive Radiation Therapy With Absorbable Spacer Hydrogel for Prostate Cancer.
PubMed 文献 · Adv Radiat Oncol · 2021-07-15

研究前瞻性纳入59例低危或有利中危局限性前列腺癌患者,全部置入SpaceOAR水凝胶后接受立体定向体部放疗、低剂量率近距离放疗、常规分割放疗或中度大分割放疗。中位随访366天,最终随访时AUA-SI评分与基线无显著变化(P=.69),EPIC-26各域评分研究期间亦无显著变化(P=.19),仅2mL直肠剂量与EPIC-26直肠评分下降相关(β=-0.002;P=.006)。作者结论认为SpaceOAR置入对危及器官剂量学有利,并预示良好的短期生活质量。

要点

  • 59例低危或有利中危局限性前列腺癌患者置入SpaceOAR水凝胶后接受根治性放疗,中位随访366天。
  • 最终随访AUA-SI评分较基线无显著变化(P=.69),EPIC-26各域评分研究期间无显著变化(P=.19)。
  • 仅2mL直肠剂量与EPIC-26直肠评分下降相关(β=-0.002;P=.006),其余剂量学指标与评分无显著关联。

核心结论

  • 作者结论认为,使用SpaceOAR可获得对危及器官有利的剂量学,并预示良好的短期生活质量;长期随访正在进行且有必要评估水凝胶的长期效应与关联。

研究设计与样本

  • 前瞻性研究,纳入59例低危或有利中危局限性前列腺癌患者,全部置入SpaceOAR水凝胶后接受立体定向体部放疗、低剂量率近距离放疗、常规分割放疗或中度大分割放疗。
  • 收集基线EPIC-26与AUA-SI评分,评估置入后危及器官剂量学,并前瞻性收集随访EPIC-26与AUA-SI评分。
  • 采用重复测量方差分析比较患者个体反应,并通过构建线性回归模型将调查数据与剂量学指标相关分析。

主要发现

  • 中位随访366天(四分位距507)。
  • 最终随访时前列腺特异性抗原较基线显著下降(P<.0001)。
  • 治疗期间无3级毒性。
  • 最终随访AUA-SI评分较基线无显著变化(P=.69),研究期间EPIC-26各域评分亦无显著变化(P=.19)。
  • AUA评分及EPIC-26评分与直肠、膀胱或尿道剂量均无显著关联,例外为2mL直肠剂量与EPIC-26直肠评分下降相关(β=-0.002;P=.006);患者报告的肠道域下降小于既往报道数据。

关键数值与推荐

  • 最终随访前列腺特异性抗原较基线显著下降(P<.0001)。
  • 最终随访AUA-SI评分较基线无显著变化(P=.69)。
  • 研究期间EPIC-26各域评分无显著变化(P=.19)。
  • 2mL直肠剂量与EPIC-26直肠评分下降相关(β=-0.002;P=.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出长期随访正在进行且有必要,以评估水凝胶的长期效应与关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SpaceOAR is a device approved for conventional radiation in prostate cancer. We sought to observe prospectively how SpaceOAR Hydrogel effected quality of life and dosimetry to organs at risk at our institution. METHODS AND MATERIALS: We prospectively enrolled patients with low risk or favorable-intermediate risk localized prostate cancer. Baseline Expanded Prostate Cancer Index Composite (EPIC-26) scores along with baseline American Urology Association Symptom Index (AUA-SI) scores were collected. SpaceOAR was placed for all patients who then received stereotactic body radiation therapy, low dose rate brachytherapy, conventionally fractionated radiation therapy, or moderately hypofractionated radiation therapy. We evaluated postimplant dosimetry to critical structures, and prospectively collected follow-up EPIC-26 and AUA-SI scores. We performed a repeated measures analysis of variance to compare patient-specific responses and correlated survey data with dosimetric metrics by generating linear regression models. RESULTS: We enrolled 59 patients in this study with a median follow-up of 366 days (interquartile range, 507). At final follow-up, the "?>prostate-specific antigen had a significant decline compared with baseline (P < .0001). There were no grade 3 toxicities on treatment. There were no significant changes in the AUA-SI score (P = .69) at final follow-up compared with baseline, nor was there any change in EPIC-26 domain scores (P = .19) during the course of the study period. There were no significant associations between AUA scores and EPIC-26 scores and the dose to the rectum, bladder, or urethra with the exception being dose to the 2 mL rectum correlated with decline in EPIC-26 rectal score (β, -0.002; P = .006). Patient-reported declines in bowel domains were less than previously reported data. CONCLUSIONS: Use of SpaceOAR results in favorable dosimetry to the organs at risk and portends excellent short-term quality of life as measured by the association with the patient reported outcome measures. Longer-term follow-up is ongoing and necessary to assess the long-term effect and association of the hydrogel.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Newman NB, Rajkumar A, Cleary RK, et al. Patient Reported Quality of Life Outcomes After Definitive Radiation Therapy With Absorbable Spacer Hydrogel for Prostate Cancer. Adv Radiat Oncol. 2021. PMID: 34934855. doi:10.1016/j.adro.2021.100755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。